Last Updated: Tuesday, 20 October 2009
Abstract
Purpose and objectives
This project aimed at developing a first set of indicators for monitoring the performance of the pharmaceutical industry in meeting public health objectives. It was driven by the G10 Medicine Group recommendation 1b “The development by the Commission of a comprehensive set of indicators covering […] the prevention and treatment of diseases and emerging health threats with reference to data on morbidity and mortality
including the performance of products…”. The intention behind this recommendation is to develop well established methods for monitoring industry competitiveness while ensuring that social and public health objectives, at national and European levels, are also brought into the picture.
Methodology
The first stage of the project consisted in defining the objectives and identifying the main issues to be considered from the patient’s perspective through consultation with public health stakeholders. The scope of the range of indicators was then identified, according to three main types:
(A) High-level indicators of pharmaceutical industry performance;
(B) Indicators for the wider pharmaceutical sector;
(C) In-depth indicators for specific disease areas: 2 case-studies were conducted for an acute and a chronic condition.
In a second stage, data availability was reviewed along with a detailed description, evaluation and recommendations for indicators covering the areas identified in the first stage. Two case-studies were also conducted for a chronic disease, diabetes mellitus, and an acute one, acute stroke. Globally, those 2 conditions account for over 7% of the EU-25 total burden of disease1.
Throughout the project, the work was carried out in regular collaboration with public health experts from national health institutes, European and worldwide organisations.
Downloads
pharma_frep_en.pdf
Tags
